Immune Response receives additional delisting notice from Nasdaq

New York, Nov. 2 - Immune Response Corp. said it received a second notice from the Nasdaq Stock Market, Inc. warning that it is not in compliance with the $1.00 minimum bid price standard for the Nasdaq Capital Market, formerly the Nasdaq Small Cap Market.

A hearing on the earlier failure to comply with listing standards is scheduled for Nov. 3 and the bid price issue will also be considered at that time.

Immune Response said it will present a plan to comply with all the standards for listing.

The latest letter says the Carlsbad, Calif., biopharmaceutical company did not meet the $1.00 minimum bid price by the end of the 180-day compliance period on Oct. 26.

Previously Immune Response received a notice that it was out of compliance because the value of its listed securities is below the $35 million threshold required by the Nasdaq Capital Market.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.